In the future, further development of selective PROTAC E3 ubiquitin ligase degraders triggering HDAC6 degradation [201] will provide further therapeutic options against various types of cancer, including CML. The gene discussed is HDAC6; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.